Identification of clinically useful cancer prognostic factors: What are we missing?

Journal of the National Cancer Institute

Volumn 97, Issue 14, 2005, Pages 1023-1025

  McShane, Lisa M ^a   Altman, Douglas G ^b   Sauerbrei, Willi ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TUMOR MARKER;

CANCER MORTALITY; CANCER RESEARCH; CONFIDENCE INTERVAL; EDITORIAL; HEAD AND NECK CANCER; HUMAN; INFORMATION PROCESSING; INFORMATION RETRIEVAL; MEDICAL LITERATURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; PUBLISHING; RELIABILITY; STANDARDIZATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; CHEMISTRY; HEAD AND NECK TUMOR; META ANALYSIS; METHODOLOGY; NOTE; OBSERVER VARIATION; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; STANDARD;

HEAD AND NECK NEOPLASMS; HUMANS; META-ANALYSIS; OBSERVER VARIATION; PROGNOSIS; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SAMPLE SIZE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 23244432214     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dji193     Document Type: Editorial

References (20)

1. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66.
2. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, et al. for the American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78.
3. Schilsky RL, Taube SE. Introduction: Tumor markers as clinical cancer tests - are we there yet? Semin Oncol 2002;29:211-2.
4. McGuire WL. Breast cancer prognostic factors: Evaluation guidelines. J Natl Cancer Inst 1991;83:154-5.
5. Fielding LP, Fenoglio-Preiser CM, Freedman LS. The future of prognostic factors in outcome prediction for patients with cancer. Cancer 1992;70:2367-77.
6. Burke HB, Henson DE. Criteria for prognostic factors and for an enhanced prognostic system. Cancer 1993;72:3131-5.
7. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med 1993;118:201-10.
8. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993;85:1206-19.
9. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994;69:979-85.
10. Gasparini G. Prognostic variables in node-negative and node-positive breast cancer. Breast Cancer Res Treat 1998;52:321-31.
11. Hall PA, Going JJ. Predicting the future: A critical appraisal of cancer prognosis studies. Histopathology 1999;35:489-94.
12. Altman DG. Systematic reviews of evaluations of prognostic variables. In: Egger M, Davey Smith G, Altman DG, eds. Systematic reviews in health care. Meta-analysis in context. 2nd ed. London (UK): BMJ Books; 2001. p. 228-47.
13. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001;323:224-8.
14. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, et al. Reporting of prognostic markers: Current problems and development of guidelines for evidence-based practice in the future. Br J Cancer 2003;88:1191-8.
15. Kyzas PA, Loizou KT, Ioannidis JPA. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 2005;97:1043-55.
16. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Systematic reviews of trials and other studies. Health Technol Assess 1998;2:1-276.
17. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: Comparison of protocols to published articles. JAMA 2004;291:2457-65.
18. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer 1995;72: 511-8.
19. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-35.
20. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. In press 2005.